News

ENABLE project video

Latvian Institute of Organic Synthesis is a member of the ENABLE consortium since 2014.

The ENABLE consortium is working to advance the development of promising new antibiotic compounds targeting Gram-negative bacteria such as Escherichia coli. The goal of the project is to develop attractive antimicrobial candidates for extensive preclinical studies and First-in-Human clinical trials, bringing new antibiotics to treat Gram-negative infections one step closer to patients.

The video introduces ENABLE, its drug discovery platform, expert network and explains how to submit an Expression of Interest (EoI).

 

Learn more about ENABLE project

New commentary article from E. Liepinsh and M. Dambrova: Letter to the Editor: “Serum Carnitine Metabolites and Incident Type 2 Diabetes Mellitus in Patients With Suspected Stable Angina Pectoris”

The Journal of Clinical Endocrinology & Metabolism (IF 2017: 5.789) published a letter to editor from E. Liepinsh and prof. M. Dambrova.

Liepins_Dambrova

Edgars Liepinsh & Maija Dambrova (2018) Letter to the Editor: “Serum Carnitine Metabolites and Incident Type 2 Diabetes Mellitus in Patients With Suspected Stable Angina Pectoris”, The Journal of Clinical Endocrinology & Metabolism, Volume 103, Issue 11, Pages 4037–4038, DOI: 10.1210/jc.2018-01408

 

New article from prof. Jirgensons group: Inhibition of O-acetylserine sulfhydrylase by fluoroalanine derivatives

The Journal of Enzyme Inhibition and Medicinal Chemistry (IF 2017: 3.638) published a research paper from prof. Jirgensons group in collaboration with Food and Drug Department, University of Parma and National Research Council, Institute of Biophysics, Pisa:

Nina Franko, Konstantinos Grammatoglou, Barbara Campanini, Gabriele Costantino, Aigars Jirgensons & Andrea Mozzarelli (2018) Inhibition of O-acetylserine sulfhydrylase by fluoroalanine derivatives, Journal of Enzyme Inhibition and Medicinal Chemistry, 33:1, 1343-1351, DOI: 0.1080/14756366.2018.1504040

10.10.2018_J.Enz

Research was supported by the MSCA-ITN-2014-ETN project INTEGRATE under Grant 642620.

Journal of Enzyme Inhibition and Medicinal Chemistry Impact Factor: 3.638 (IF 2017).

LIOS joined the EURAXESS Latvia network

euraxcess-2

Latvian Institute of Organic Synthesis has become a member of EURAXESS Latvia network in  September 2018.

The main task of EUROAXESS Latvia network is to provide information and consult researchers on possibilities of scientific career in Latvia as well as practically support researchers and their families to plan and organize their move to Latvia.

EURAXESS is a pan-European initiative launched by the European Commission with the aim to support mobile researchers and their family members on their relocation to another country.

PELARGODONT project progress meeting in Riga

On April 6 (2018) M-era.Net project PELARGODONT progress meeting took place at the Latvian Institute of Organic Synthesis (LIOS). Our researchers discussed the results achieved within the project and coordinated future cooperation with Lithuanian, Polish and Italian partners.

Dr. Pharm. Elina Makarova reported results of the LIOS research.

PELARGODONT project team photo:

Pelargodont-06.04.2018

 

Pelargodont-06.04.2018(2)

Learn more about PELARGODONT project!

EU-OPENSCREEN, the European research infrastructure for chemical biology, gains ERIC status

On March 21, 2018 the European Commission has granted the status of European Research Infrastructure Consortium (ERIC) to EU-OPENSCREEN setting up a Pan European RI for Chemical Biology. The award of the European Research Infrastructure Consortium (ERIC) status by the European Commission was preceded by an extensive and excellence-based selection process in many member countries and the ESFRI (European Strategy Forum for Research Infrastructures) forum, a committee of representatives of the country ministries. EU-FLAG_cmyk_304dpi_small
EU-openscreen

EU-OPENSCREEN-ERIC with its headquarters based in Berlin on the Science Campus Buch was founded by 7 European Member States: the Czech Republic, Finland, Germany, Latvia, Norway, Poland and Spain. Denmark will participate as an observer and as a full member from 2019. Seven more countries are preparing their participation.

24 institutes (screening centres and chemistry centres) and a data centre were selected as partner institutes of EU-OPENSCREEN ERIC in the member countries in an independent evaluation process.

The national node of EU-OPENSCREEN in Latvia is Institute of Organic Synthesis.
The primary objective of EU-OPENSCREEN is to create a distributed research infrastructure which meets the needs of its user groups – scientists seeking a better understanding on how fundamental molecular processes act to govern biological function at the organismal, tissue, cellular and pathway levels. The majority of these scientists in Europe, however at present, do not have access to such technology platforms and compound collections, which are generally very costly to purchase, operate and maintain. EU-OPENSCREEN will cost-effectively overcome these limitations by involving and providing access to Europe’s leading screening platforms and chemistry groups, constructing a jointly used compound collection and operating an open-access bioactivity database which will be accessible on a global basis.
EU-OPENSCREEN is already cooperating with thirteen of the new Biomedical Sciences (BMS) research infrastructures in the European cluster project CORBEL to jointly create harmonised access for users to their complementary biological and medical technologies, biological samples and data services required for state-of-the-art biomedical research and development. To promote new applications derived from marine organisms in areas such as drug discovery, novel foods and food ingredients, selective breeding in aquaculture, biosanitation, cosmetics and bioenergy, EU-OPENSCREEN is also part of the European cluster project EMBRIC. Beyond Europe, EU-OPENSCREEN cooperates with similar consortia in the USA and Australia.

Learn more about EU-OPENSCREEN!